Tata Consultancy Services (TCS) has announced a strategic partnership with Dassault Systems, within the framework of the Living Heart Project. This initiative brings together a diverse ecosystem of cardiovascular experts, educators, medical device innovators, regulatory bodies such as the US FDA, and practicing cardiologists. The goal is to create and validate lifelike digital simulations of the human heart.
The project aims to pioneer groundbreaking medical solutions, including leveraging heart simulations as a digital evidentiary source for securing approvals for novel cardiovascular devices. This involves conducting in-silico clinical trials, which could serve as a supplement to clinical data, reducing the necessity for animal testing and human subject enrollment in traditional clinical trials.
TCS intends to contribute its domain knowledge, technological proficiency, and its ongoing work on the Digital BioTwin of the heart to refine, simulate, and implement technology in the development and validation of highly precise, individualized digital models of the human heart.
The TCS Digital BioTwin is a biophysics-based computational model developed by TCS researchers, enabling remote and non-invasive investigation of specific human organs. It aids in comprehending the distinct contributions of various factors and analyzing their interactions on a spatial scale. TCS has been engaged in research to create digital bio-twins of organs such as the skin, nose, and colon. In conjunction with Dassault Systems and other collaborators, TCS aims to realize a Virtual Human Twin, focusing on specific critical organs to advance the field.
Steve Levine, Senior Director of Virtual Human Modeling at Dassault Systèmes and founder of The Living Heart Project, expressed enthusiasm about TCS joining the Living Heart Project, highlighting the company’s research and technology development expertise. Levine emphasized the shared commitment to leveraging virtual environments for advancements in medical science and patient care, aiming to accelerate innovation and deliver personalized in-silico medical solutions.
Vikram Karakoti, Global Head of the Life Sciences Business at TCS, expressed excitement about participating in the Living Heart initiative. He anticipates that this collaboration will lead to a groundbreaking digital simulation of the human heart, enhancing understanding of cardiac function and providing insights for innovative cardiac treatments and new product development in the medical technology and pharmaceutical sectors. Karakoti underscored TCS’s experience in creating digital bio-twins for various organs and body parts as a valuable contribution to this collaborative effort.
